Tarsus Pharmaceuticals Net Worth
Tarsus Pharmaceuticals Net Worth Breakdown | TARS |
Tarsus Pharmaceuticals Net Worth Analysis
Tarsus Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tarsus Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tarsus Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tarsus Pharmaceuticals' net worth analysis. One common approach is to calculate Tarsus Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tarsus Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tarsus Pharmaceuticals' net worth. This approach calculates the present value of Tarsus Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tarsus Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tarsus Pharmaceuticals' net worth. This involves comparing Tarsus Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tarsus Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Tarsus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tarsus Pharmaceuticals' net worth research are outlined below:
Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
Tarsus Pharmaceuticals has high historical volatility and very poor performance | |
The company reported the previous year's revenue of 182.95 M. Net Loss for the year was (115.55 M) with profit before overhead, payroll, taxes, and interest of 116.74 M. | |
Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (83.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
Over 91.0% of the company shares are owned by institutional investors | |
Latest headline from simplywall.st: Tarsus Pharmaceuticals Full Year 2024 Earnings Beats Expectations |
Tarsus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tarsus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tarsus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
11th of March 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
11th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Tarsus Pharmaceuticals Target Price Consensus
Tarsus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Tarsus Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
9 | Strong Buy |
Most Tarsus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Tarsus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Tarsus Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationTarsus Pharmaceuticals Target Price Projection
Tarsus Pharmaceuticals' current and average target prices are 43.55 and 66.00, respectively. The current price of Tarsus Pharmaceuticals is the price at which Tarsus Pharmaceuticals is currently trading. On the other hand, Tarsus Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Tarsus Pharmaceuticals Market Quote on 28th of February 2025
Target Price
Analyst Consensus On Tarsus Pharmaceuticals Target Price
Know Tarsus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tarsus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tarsus Pharmaceuticals backward and forwards among themselves. Tarsus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tarsus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | |||
Amvescap Plc. | 2024-12-31 | 932.1 K | |
State Street Corp | 2024-12-31 | 916.9 K | |
Jpmorgan Chase & Co | 2024-09-30 | 880.3 K | |
Geode Capital Management, Llc | 2024-12-31 | 838.8 K | |
Macquarie Group Ltd | 2024-12-31 | 815.9 K | |
Artisan Partners Limited Partnership | 2024-12-31 | 691.3 K | |
Millennium Management Llc | 2024-12-31 | 644 K | |
Ikarian Capital, Llc | 2024-12-31 | 607.7 K | |
Ensign Peak Advisors Inc | 2024-12-31 | 570.1 K | |
Blackrock Inc | 2024-12-31 | 3.5 M | |
Rtw Investments, Llc | 2024-12-31 | 3.2 M |
Follow Tarsus Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.67 B.Market Cap |
|
Project Tarsus Pharmaceuticals' profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.31) | (0.33) | |
Return On Capital Employed | (0.41) | (0.43) | |
Return On Assets | (0.31) | (0.32) | |
Return On Equity | (0.51) | (0.49) |
When accessing Tarsus Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tarsus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tarsus Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Tarsus Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tarsus Pharmaceuticals. Check Tarsus Pharmaceuticals' Beneish M Score to see the likelihood of Tarsus Pharmaceuticals' management manipulating its earnings.
Evaluate Tarsus Pharmaceuticals' management efficiency
Tarsus Pharmaceuticals has return on total asset (ROA) of (0.2346) % which means that it has lost $0.2346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5483) %, meaning that it created substantial loss on money invested by shareholders. Tarsus Pharmaceuticals' management efficiency ratios could be used to measure how well Tarsus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2025. Return On Capital Employed is likely to drop to -0.43 in 2025. At this time, Tarsus Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 15.4 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 114 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 5.97 | 4.14 | |
Tangible Book Value Per Share | 5.75 | 4.10 | |
Enterprise Value Over EBITDA | (19.27) | (20.24) | |
Price Book Value Ratio | 9.27 | 9.74 | |
Enterprise Value Multiple | (19.27) | (20.24) | |
Price Fair Value | 9.27 | 9.74 | |
Enterprise Value | 1.9 B | 1.9 B |
The strategic initiatives led by Tarsus Pharmaceuticals' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 7.731 | Revenue | Quarterly Revenue Growth 4.079 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tarsus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tarsus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tarsus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tarsus Pharmaceuticals Corporate Filings
8K | 25th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13th of February 2025 Other Reports | ViewVerify | |
F3 | 15th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Tarsus Pharmaceuticals Earnings per Share Projection vs Actual
Tarsus Pharmaceuticals Corporate Management
Leonard JD | Chief Officer | Profile | |
Scott Youmans | Vice Sales | Profile | |
Seshadri Neervannan | Chief Officer | Profile | |
Adrienne Kemp | Senior Communications | Profile | |
Elizabeth MD | Chief Director | Profile | |
Aziz MBA | Chief Officer | Profile |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.